Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

SABCS 2012

Published: 12 Dec 2012

Views: 3176

Rating:

Save

Dr Peter Kaufman - Norris Cotton Cancer Center, New Hampshire, USA

At a press conference at SABCS 2012, Dr Peter Kaufman presents data on a A phase III multicenter study of eribulin mesylate in women with previously treated metastatic breast cancer failed to meet its co-primary endpoints of improved progression-free survival and overall survival compared with capecitabine.

Read more in ecancerNews.

Related Videos

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

SABCS 2023: Highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2023: Highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Preoperative endocrine therapy in premenopausal women leads to sparing...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

Zanidatamab, palbociclib and fulvestrant show positive results in treating...

Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO)...

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2...

Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new...

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Trial investigates multiparametric prognostic score in early HR+/HER2- breast...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

More from ecancer